West Announces Third Quarter 20...((3.9) -1 1.8 1 (2.8) - ...),Health

Date:11/3/2009

(3.9) -1 1.8 1 (2.8) - (3.6) - Other expense, net 0.3 - 0.2 - 0.3 - 0.8 - --- -- --- -- --- -- --- -- Operating profit 25.9 10 17.9 7 75.8 10 98.5 12 Interest expense, net 3.5 1 3.9 2 10.5 1 10.5 1 --- -- --- -- ---- -- ---- -- Income before income taxes 22.4 9 14.0 5 65.3 9 88.0 11 Income tax expense 6.0 2 0.8 - 14.6 2 20.0 3 Equity in net income of affiliated companies 0.8 - 0.3 - 1.6 - 0.8 - --- -- --- -- --- -- --- -- Net Income 17.2 7% 13.5 5% 52.3 7% 68.8 8% Less: net income attributable to noncontrolling interests - 0.2 - 0.5 -- --- -- --- Net income attributable to common shareholders $17.2 $13.3 $52.3 $68.3 ===== ===== ===== ===== Net income per share attributable to common shareholders: Basic $0.52 $0.41 $1.60 $2.11 Assuming Dilution $0.50 $0.40 $1.53 $1.98 ----- ----- ----- ----- Average common shares outstanding 32.9 32.5 32.8 32.4 Average shares assuming dilution 36.4 36.2 36.3 36.1 WEST PHARMACEUTICAL SERVICES REPORTING SEGMENT INF
'/>"/>

SOURCE West Pharmaceutical Services, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study